Title:
Omicron outbreak at a private gathering in the Faroe Islands, infecting 21 of 33 triple-vaccinated healthcare workers

Running title:
Omicron outbreak in the Faroe Islands

Authors
Gunnhild Helmsdal; General Practitioner Service, Vestmanna, Faroe Islands
Olga K Hansen; Office of the Chief Medical Officer, Tórshavn, Faroe Islands
Lars F Møller; Office of the Chief Medical Officer, Tórshavn, Faroe Islands
Debes H Christiansen; Faroese Food and Veterinary Authority, Tórshavn, Faroe Islands
Maria Skaalum Petersen; Department of Occupational Medicine and Public Health, Faroe Islands
Hospital Service, Tórshavn, Faroe Islands; Center of health Science, University of the Faroe Islands,
Tórshavn, Faroe Islands
Marnar F Kristiansen; Center of health Science, University of the Faroe Islands, Tórshavn, Faroe Islands;
Faroe Islands Hospital Service, Tórshavn, Faroe Islands

Corresponding author:
Gunnhild Helmsdal, gunhe@ls.fo, Garðatún 12, 350 Vestmanna, Faroe Islands

Alternate corresponding author:
Marnar Fríðheim Kristiansen, marfr@ls.fo, J.C. Svabos göta 14, Tórshavn, Faroe Islands

Keywords
Omicron; breakthrough infection; COVID-19; super spreading; vaccination
Abstract

There are concerns that the SARS-CoV-2 Omicron variant evades immune responses due to unusually high numbers of mutations on the spike protein. Here we report a super-spreading event of Omicron infections amongst triple-vaccinated healthcare workers, infecting 21 of 33 attending a private gathering in the Faroe Islands.
South African researchers were the first to report the B.1.1.529 variant of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) on November 24 [1]. Two days later, WHO named the variant Omicron and classified it as a variant of concern (VOC) [2].

The Omicron variant carries from 26 to 32 mutations on the spike protein, the main antigenic target of antibodies generated by infection or vaccination [3,4]. Early reports suggest that Omicron displays higher transmissibility and immune escape potential than earlier variants, while a neutralization study has shown lower neutralization activity for previously infected and vaccinated against the Omicron variant [5].

Although many countries worldwide have enacted travel restrictions to restrict the transmission of the Omicron variant, the variant has managed to spread quickly within Europe and beyond during the first weeks of December 2021. The fast spread has led to the expectation that the Omicron variant will become the dominating variant within a short time, and surveillance of the severity and transmissibility of the Omicron variant is critical in the following weeks and months [6].

The Faroe Islands, a self-governing group of islands located between Iceland and Norway, have been relatively successful in containing the COVID-19 pandemic [7,8]. On December 30, 2020, the first Faroese received the BNT162b2 vaccine (Comirnaty; BioNTech, Mainz, Germany), the only vaccine used in the Faroe Islands, and since a high proportion of the population has been vaccinated. As of December 8, 74.6% of the population has been vaccinated two times, and 13.6% three times [9]. From March 2020 to September 2021, the Faroe Islands had registered only 1,001 cases of COVID-19 (1,867 per 100,000) and two deaths (3.73 per 100,000). However, after loosening restrictions and the introduction of the more contagious Delta variant, a large outbreak has plagued the islands, with more than 3,300 cases and 11 deaths registered during the last two and a half months [9].
This paper reports a super-spreading event where 21 of 33 healthcare workers were infected with the Omicron variant after attending a social gathering in early December 2021, even though all infected participants had been vaccinated three times and had a recent negative test.

**Methods**

The Chief Medical Officer’s office performs contact tracing in the Faroe Islands by interviewing all SARS-CoV-2 positive individuals and identifying their close contacts and their vaccination status [7]. Usually, only SARS-CoV-2 naive contacts are asked to quarantine. However, since the emergence of Omicron, all contacts to suspected Omicron positive individuals are asked to quarantine for seven days. They are also asked to get a PCR test immediately and on days 4 and 6, regardless of vaccination status. All positive individuals are required to isolate.

The Faroe Islands have performed among the highest numbers of COVID-19 tests per capita globally. Throat swabs are offered freely at several testing centers set up by the government, after which PCR analysis is performed at one of two centralized laboratories, with test results usually delivered within 12-24 hours. All cases connected to foreign travel, or where the Omicron variant is suspected, are genome sequenced by targeted sequencing, where parts of the spike protein are sequenced. This method is faster than performing whole genome sequencing on the virus, allowing for more cases to be screened.

All the positive individuals from the gathering agreed to participate in this study. They were interviewed by staff at the Chief Medical Officer’s office twice. First time was shortly after the positive test where they recorded date of symptom debut, vaccination status, and personal characteristics, and the second time 12-14 days after the exposure where symptoms, comorbidities, and medication were registered.
Results

During early December 2021, 33 persons attended a private gathering. Several participants noticed symptoms during the following days and performed a PCR test, which was positive. The other participants subsequently also performed PCR tests, resulting in 21 of 33 participants testing positive, corresponding to an attack rate of 63.6%. The unusually high attack rate led the Chief Medical Officer to request genome sequencing of the virus, identifying the first Omicron variant in the Faroes on December 8. So far, 13 samples from the gathering, and an additional four from the extended transmission chain, have been verified as the Omicron variant through targeted sequencing. The remaining cases are also assumed to be the Omicron variant. It has not been possible to definitively identify the index case initiating this transmission chain, but presumably, the variant has been imported from abroad.

All infected participants were fully vaccinated with the mRNA vaccine BNT162b2 (Comirnaty; BioNTech, Mainz, Germany) and had received a third booster dose within the last two and a half months, and none had a history of previous SARS-CoV-2 infection. The characteristics of the participants are displayed in Table 1. All infected participants had a negative test taken within 36 hours before the gathering. Most had performed a PCR test, while five had taken a lateral flow test. All the infected individuals experienced symptoms. The most common symptoms were muscle and joint pain, fatigue, and fever, while the least common symptoms were loss of taste and smell. No one was admitted to the hospital.

If we assume that the exposure to SARS-CoV-2 was on the evening of the gathering, the incubation period was short, ranging from 2 to 6 days, with a mean incubation period of 3.24 days (95% CI 2.87-3.60). Time to resolution of symptoms varied, and at the end of follow-up, five individuals still reported symptoms, while the rest reported symptoms lasting 1 to 9 days.
Discussion

This report demonstrates that the Omicron variant can lead to super-spreading events even in triple-vaccinated people. All the reported cases were symptomatic. None were admitted to the hospital. There is an urgent need for research into the Omicron variant, as with the current growth rates, it is anticipated to dominate the spread within a short time [10].

The primary spread of SARS-CoV-2 is through human-to-human transmission, either through respiratory droplets or aerosols. Factors such as indoor settings, poor ventilation, loud talking, laughing, and singing will increase the likely spread of the virus [11]. This study shows the ongoing importance of social distancing and the avoidance of larger festive gatherings during the pandemic in preventing possible super-spreading events. The active transmission chain described in this study was seemingly stopped after about 70 cases, demonstrating that through effective contact tracing, an Omicron transmission chain can be contained.

There is still limited clinical data available on the Omicron variant. However, Brandal et al. have reported a similar outbreak to the one reported in this paper in Norway, with an high attack rate of 74%, and similar symptoms to the cases reported here [12]. Furthermore, Espenhain et al. have published an early report on the first 785 Omicron cases in Denmark. They highlight the rapid spread of this variant and the ability to induce super-spreading events and that a high proportion of the infected was fully vaccinated. Since there is a lag time from infection to hospitalization and death, and this variant has only recently been discovered, sufficient data is not available to make conclusions on the severity yet [13].
Our findings indicate that the Omicron variant displays potent immune-escape properties and that even individuals recently boosted are at risk of getting infected. The incubation period of Omicron was short in this study. If the incubation period for Omicron is shorter than for previous variants, this can potentially partly explain the increased infection in individuals with some immunity. It is not possible to determine hospitalization rate or death rates from this small study. We do not yet know the risk of developing Long Covid after an Omicron infection. Even if the cases in this study primarily experienced relatively mild disease, all the reported cases have had previous immunity through vaccination. It is notable, that all the infected cases experienced symptoms, and that especially loss of taste and smell seem to be less common in these cases, compared with previous outbreaks. It is likely that vaccination also protects against severe disease with the Omicron variant, even if protection against infection has waned to some degree, still underlining the importance of vaccination. Of note, the findings might not generalize to SARS-CoV-2 naive individuals, and for this reason, further research in Omicron amongst SARS-CoV-2 naive individuals is needed.

**Author contributions**

GH and MFK wrote the manuscript. OKH and LFM were responsible for contact tracing and interviewing the participants. DHC was responsible for the sequencing of the viral genomes. GH, OKH, LFM, DC, MSP and MFK contributed to the interpretation of data and read, edited, and approved the final manuscript.

**Acknowledgements**

We would like to thank the staff at the Chief Medical Officer’s office and at the Faroese Food and Veterinary Authority, for their tireless work in connection with the COVID-19 pandemic.

**Funding**

No funding was received for this paper.
Conflict of interest

The authors report no conflicts of interest.

Ethical statement

The Faroese Ethical Committee ruled that this project belonged to the category of registry research, and was not obliged to seek approval from the committee.
Table 1: Personal characteristics and symptoms of Omicron infected individuals (n=21) from a gathering in the Faroe Islands

| Personal characteristics and symptoms | Symptoms (%) | Mild symptoms (%) | Moderate symptoms (%) | Severe symptoms (%) |
|---------------------------------------|--------------|-------------------|-----------------------|---------------------|
| **Age, median**                       | 45 years     |                   |                       |                     |
| **Date of 1\textsuperscript{st} vaccination\*** | 04-01-2021 to 15-01-2021 |                   |                       |                     |
| **Date of 2\textsuperscript{nd} vaccination\*** | 05-02-2021 to 04-03-2021 |                   |                       |                     |
| **Date of 3\textsuperscript{rd} vaccination\*** | 28-10-2021 to 02-12-2021 |                   |                       |                     |
| **Any comorbidity, n (%)**            | 4 (19%)      |                   |                       |                     |
| **Any medication, n (%)**             | 3 (14%)      |                   |                       |                     |

| Symptom               | Asymptomatic | Fever | Headache | Dry cough | Wet cough | Dyspnea | Loss of smell | Loss of taste | Fatigue | Rhinorrhea | Sinuses | Throat pain | Myalgia | Arthralgia | Chest pain |
|-----------------------|--------------|-------|----------|-----------|-----------|---------|---------------|--------------|---------|------------|---------|------------|---------|-----------|------------|
|                      | 0 (0%)       | 13 (62%) | 11 (52%) | 13 (62%) | 8 (38%)  | 8 (38%) | 4 (19%)       | 5 (24%)      | 15 (71%)| 12 (57%)  | 6 (29%) | 10 (48%)   | 13 (62%)| 11 (52%)  | 4 (19%)    |
| Symptoms (%)          |              | 0 (0%) | 9 (69%)  | 4 (36%)   | 9 (69%)  | 7 (88%) | 1 (25%)       | 2 (40%)      | 4 (27%) | 5 (42%)   | 3 (50%) | 7 (70%)    | 7 (54%) | 7 (64%)   | 2 (50%)    |
| Mild symptoms (%)     |              | 0 (0%) | 3 (23%)  | 5 (45%)   | 3 (23%)  | 1 (13%) | 3 (75%)       | 3 (60%)      | 7 (47%) | 3 (25%)   | 1 (17%) | 2 (20%)    | 4 (31%) | 3 (27%)   | 2 (50%)    |
| Moderate symptoms (%) |              |        |          |           |          |         |               |              |         |           |         |            |         |           |            |
| Severe symptoms (%)   |              |        |          |           |          |         |               |              |         |           |         |            |         |           |            |

* All infected individuals had received three vaccinations
References

1. Science Brief: Omicron (B.1.1.529) Variant | CDC. Available at:
   https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html. Accessed 13 December 2021.

2. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. Available at:
   https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern. Accessed 13 December 2021.

3. SARS-CoV-2 Variants - Stanford Coronavirus Antiviral & Resistance Database (CoVDB). Available at: https://covdb.stanford.edu/page/mutation-viewer/#omicron. Accessed 13 December 2021.

4. World Health Organization HQ. Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States. Available at:
   https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states?fbclid=IwAR2N3613MxneZEWO00HXGSRZy0BPLRTc0JlyGumdfVtGWzTYA3vzdrcGY. Accessed 13 December 2021.

5. Cele S, Jackson L, Khan K, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv 2021; 2021.12.08.21267417. Available at:
   http://medrxiv.org/content/early/2021/12/11/2021.12.08.21267417.abstract.

6. Lesley S, Nei-yuan H, Sikhuline M, et al. Track Omicron’s spread with molecular data. Science (80-) 2021; 0:eabn4543. Available at: https://doi.org/10.1126/science.abn4543.

7. Kristiansen M, Heimustovu B, Borg Sá, et al. Epidemiology and Clinical Course of First Wave Coronavirus Disease Cases, Faroe Islands. Emerg Infect Dis J 2021; 27. Available at:
   https://wwwnc.cdc.gov/eid/article/27/3/20-2589_article.

8. Strøm M, Kristiansen MF, Christiansen DH, Weihe P, Petersen MS. Elimination of COVID-19 in the
Faroe Islands: effectiveness of massive testing and intensive case and contact tracing. Lancet Reg Heal - Eur 2020; 0:100011. Available at: https://linkinghub.elsevier.com/retrieve/pii/S2666776220300119. Accessed 29 December 2020.

9. Statistics - Korona í Føroyum. Available at: https://korona.fo/statistics. Accessed 13 December 2021.

10. European Centre for Disease Prevention and Control. Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the context of the ongoing Delta VOC transmission in the EU/EEA, 18th update. Stockholm: 2021. Available at: https://www.ecdc.europa.eu/en/publications-data/covid-19-assessment-further-emergence-omicron-18th-risk-assessment. Accessed 17 December 2021.

11. Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta 2020; 508:254–266. Available at: https://pubmed.ncbi.nlm.nih.gov/32474009.

12. Brandal LT, MacDonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Eurosurveillance 2021; 26. Available at: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.50.2101147.

13. Espenhain L, Funk T, Overvad M, et al. Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark, December 2021. Eurosurveillance 2021; 26. Available at: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.50.2101146.